SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ:AFFX) today announced the full commercial launch of its SNP Array 5.0, the company’s most comprehensive single array for genetic studies. Researchers are currently using the SNP Array 5.0 to better identify and understand complex diseases such as autism, autoimmunity, bipolar disease, cancer, diabetes and heart disease.
